The vascular neurologist at Allegheny Health Network provided an overview of the RapidAI and how it is evolving the way clinicians manage and treat patients who present with stroke. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
"We are able to be notified of the patients in the outlying hospitals with positive scans or large vessel occlusions as the scan gets done. By the time the radiologist is calling the emergency room, the emergency department is calling us for a transfer, we already are aware of this patient that may be potential candidate for an acute stroke therapy."
Delivered via mobile device, desktop and PACS, the Rapid clinical platform leverages artificial intelligence (AI) to create enhanced, high-quality images from NCCT, CTA, CTP, and MRI diffusion and perfusion data, to help physicians make expedient diagnoses and treatment and transfer decisions. Since its creation, RapidAI has been used in over 1800 hospitals, over 100 countries, and in 14 clinical trials globally.
The flexible platform is compatible in several different hospital environments, including emergency departments, trauma centers, acute stroke ready hospitals, primary stroke centers, and comprehensive stroke centers. Additionally, it was developed using the National Institutes of Standards and Technology cybersecurity framework and is also HIPAA and GDPR compliant. Considered the gold standard for advanced vascular imaging worldwide, RapidAI has been approved in several different countries outside of the US, including Canada and Japan.
Russell Cerejo, MD, vascular neurologist, Allegheny Health Network, has had first-hand experience using the software. Working in a large healthcare system, he believes there are several advantages brought on by RapidAI, led by its ability to improve multilevel communication. He sat down for an interview with NeurologyLive® to outline the software and the benefits it brings to treat acute stroke.